SRD5A2 gene
steroid 5 alpha-reductase 2

Normal Function

The *SRD5A2* gene provides instructions for making an enzyme called steroid 5-alpha reductase 2. This enzyme is involved in processing androgens, which are hormones that direct male sexual development. Specifically, the enzyme is responsible for a chemical reaction that converts the hormone testosterone to a more potent androgen, dihydrotestosterone (DHT), in male reproductive tissues.

Testosterone and DHT are essential for the normal development of male sex characteristics. Before birth, testosterone is responsible for the formation of internal male genitalia, including the tubes that collect sperm and carry it out of the testes (the epididymis and vas deferens) and glands that help produce semen (the seminal vesicles). DHT directs the development of the external genitalia, including the penis and scrotum, and the prostate gland. During puberty, these two hormones also play an important role in the development of male secondary sex characteristics such as the growth of facial and body hair, increased muscle mass, and deepening of the voice.

Health Conditions Related to Genetic Changes

5-alpha reductase deficiency

About 50 mutations in the *SRD5A2* gene have been identified in people with 5-alpha reductase deficiency. Most of these mutations change single protein building blocks (amino acids) in steroid 5-alpha reductase 2. Some of these genetic changes render the enzyme completely inactive. Other mutations reduce but do not eliminate the enzyme's function.

As a result of *SRD5A2* mutations, the body cannot effectively convert testosterone to DHT in reproductive tissues. A shortage of DHT disrupts the formation of external genitalia before birth. People with 5-alpha reductase deficiency are genetically male, with one X and one Y chromosome in each cell, but they may be born with external genitalia that look predominantly female, or that are not clearly male or clearly female (sometimes called ambiguous genitalia). Other affected infants have external genitalia that appear predominantly male, but they often have an unusually small penis (micropenis) and the urethra opening on the underside of the penis (hypospadias).

During puberty, the testes produce more testosterone. Researchers believe that people with 5-alpha reductase deficiency develop secondary male sex characteristics in response to higher levels of this hormone. Some affected people also retain a
small amount of 5-alpha reductase 2 activity, which may produce DHT and contribute to the development of secondary sex characteristics during puberty.

**Prostate cancer**

**Cancers**

Certain normal variations (polymorphisms) in the *SRD5A2* gene may be associated with prostate cancer. Two of these polymorphisms have been studied extensively. The most common variation replaces the amino acid valine with the amino acid leucine at position 89 in steroid 5-alpha reductase 2 (written as Val89Leu or V89L). The other variation replaces the amino acid alanine with the amino acid threonine at position 49 in the enzyme (written as Ala49Thr or A49T). Some studies have suggested that these variations are associated with an increased risk of developing prostate cancer or having a more aggressive form of the disease. Other studies, however, have not shown these associations. It remains unclear what role *SRD5A2* polymorphisms play in prostate cancer risk.

Some gene mutations are acquired during a person's lifetime and are present only in certain cells. These changes, which are called somatic mutations, are not inherited. Studies have shown that somatic *SRD5A2* mutations in prostate cancer cells may be associated with the progression of prostate cancer. These mutations may increase the activity of steroid 5-alpha reductase 2, which would raise the levels of DHT in prostate tissue. Research has shown that androgens such as DHT can stimulate prostate cancer growth.

**Other disorders**

In women, certain polymorphisms in the *SRD5A2* gene may affect the risk of developing a condition called polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess body hair (hirsutism), and weight gain. Some genetic variations increase the activity of steroid 5-alpha reductase 2 in the ovaries, which could contribute to the signs and symptoms of this condition. Other variations, including the common polymorphism Val89Leu, reduce the activity of steroid 5-alpha reductase 2 and are associated with a reduced risk of developing PCOS.
**Chromosomal Location**

Cytogenetic Location: 2p23.1, which is the short (p) arm of chromosome 2 at position 23.1

Molecular Location: base pairs 31,522,480 to 31,665,651 on chromosome 2 (Homo sapiens Updated Annotation Release 109.20200522, GRCh38.p13) (NCBI)

Credit: Genome Decoration Page/NCBI

**Other Names for This Gene**

- 3-oxo-5 alpha-steroid 4-dehydrogenase 2
- 5 alpha-SR2
- MGC138457
- S5A2_HUMAN
- SR type 2
- steroid 5-alpha-reductase 2
- steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)
- Type II 5-alpha reductase

**Additional Information & Resources**

**Educational Resources**

- Developmental Biology (sixth edition, 2000): Testosterone and Dihydrotestosterone
  https://www.ncbi.nlm.nih.gov/books/NBK9967/#A4126
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28SRD5A2%5BTIAB%5D%29+OR+%28steroid-5-alpha+reductase%5BTIAB%5D%29+OR+%285-alpha+reductase%5BTIAB%5D%29+OR+%28steroid+5alpha+reductase%5BTIAB%5D%29+OR+%28testosterone+5-alpha-reductase%5BTIAB%5D%29+OR+%28delta+4-reductase%5BTIAB%5D%29%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- POLYCYSTIC OVARY SYNDROME 1
  http://omim.org/entry/184700
- PROSTATE CANCER
  http://omim.org/entry/176807
- STEROID 5-ALPHA-REDUCTASE 2
  http://omim.org/entry/607306

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/SRD5A2ID42385ch2p23.html
- Cancer Genetics Web
  http://www.cancerindex.org/geneweb/SRD5A2.htm
- ClinVar
- HGNC Gene Symbol Report
- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:6716
- NCBI Gene
- UniProt
  https://www.uniprot.org/uniprot/P31213
Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14991867
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16849416
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11845321
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15326487
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12869400
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7979239
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16018939
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12843198
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15266301
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8262007


Reviewed: April 2008
Published: June 23, 2020